NCT07211230Not yet recruiting
Collagenase Biobank Study
Collagenase Producing Bacteria as a Biomarker and Driver of Diet-induce Colorectal Cancer Recurrence and Metastasis Following Surgery
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to look at how bacteria present within the stool at the time of surgery and postoperatively may contribute to the development of cancer recurrence after surgery. By collecting stool and blood before and after surgery, the researchers hope to determine if certain types of bacteria, or products that the bacteria produce, promote the development of tumors after surgery. By collecting tumor tissue and growing cell lines, we hope this will help researchers better understand the behavior of these types of tumors.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 107 (estimated)
- First submitted
- 5 Sept 2025
- Start date
- Dec 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- University of Chicago
- Diseases
- Colorectal cancer
- NCT number
- NCT07211230
What you commit to
- Study type: Observational
- Planned participants: 107
- From Dec 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prebiotic exposure within 30 days of surgery.
Other illness
- Stage IV colon adenocarcinoma (known metastatic disease).
- Intravenous or oral antibiotic exposure within 30 days of surgery to treat an infection.
- History of neoadjuvant chemotherapy/radiation to treat the primary colon adenocarcinoma.
- History of chemotherapy/radiation to treat a separate malignancy within the last 6 months.
- Allergy to perioperative medications (oral neomycin/metronidazole for preoperative bowel preparation, intraoperative prophylactic intravenous cefoxitin).
- Patients with a history of inflammatory bowel disease.
- Patients with a history of bariatric surgery.
- History of eating disorders.
Other
- History or current ileostomy or colostomy.
- Patients who are pregnant.
Who the study is looking for
- English speaking.
- All genders, races, and ethnicities.
- Aged greater or equal to 18 years of age.
- Ability to understand and the willingness to sign a written informed consent form.
- Diagnosed with a colon adenocarcinoma or presumed adenocarcinoma in which surgical resection is recommended.
- Have a planned surgical resection of the colon adenocarcinoma at the University of Chicago Comprehensive Cancer Center.
- Reside within 150 miles of the University of Chicago Comprehensive Cancer Center.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.